Interaction of Multimicrobial Synthetic Inhibitor 1,2-Bis(2-Benzimidazolyl)-1,2-Ethanediol with Serum Albumin: Spectroscopic and Computational Studies

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Kamtekar, Nayana ^a   Pandey, Anita ^a   Agrawal, Neeraj ^a   Pissurlenkar, Raghuvir R S ^b   Borana, Mohanish ^a   Ahmad, Basir ^a  

^a UNIVERSITY OF MUMBAI   (India)

^b BOMBAY COLLEGE OF PHARMACY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

1,2 BIS (2 BENZIMIDAZOLYL) 1,2 ETHANEDIOL; ANTIINFECTIVE AGENT; BOVINE SERUM ALBUMIN; CYSTEINE; ISOLEUCINE; PHENYLALANINE; UNCLASSIFIED DRUG; VALINE;

ARTICLE; BINDING AFFINITY; BINDING SITE; CIRCULAR DICHROISM; COMPLEX FORMATION; DRUG STRUCTURE; ENTHALPY; ENTROPY; FLUORESCENCE; HYDROGEN BOND; HYDROPHILICITY; HYDROPHOBICITY; MEAN RESIDENCE TIME; MOLECULAR DOCKING; MOLECULAR MODEL; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN FOLDING; PROTEIN STABILITY; PROTON NUCLEAR MAGNETIC RESONANCE; SPECTROSCOPY; THERMODYNAMICS; ULTRAVIOLET RADIATION;

ANIMALS; ANTI-INFECTIVE AGENTS; BENZIMIDAZOLES; BINDING SITES; CATTLE; HYDROGEN BONDING; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; KINETICS; MODELS, CHEMICAL; MOLECULAR DOCKING SIMULATION; PROTEIN BINDING; PROTEIN FOLDING; PROTEIN INTERACTION DOMAINS AND MOTIFS; SERUM ALBUMIN, BOVINE; SPECTROMETRY, FLUORESCENCE; TEMPERATURE; THERMODYNAMICS;

BACTERIA (MICROORGANISMS); CANDIDA ALBICANS; POLIOVIRUS; RHINOVIRUS;

EID: 84871902861     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0053499     Document Type: Article

References (50)

1. Thomas GL, Johannes CW, (2011) Natural product-like synthetic libraries. Curr Opin Chem Biol 15: 516-522.
2. de Azevedo WF Jr, Dias R, (2008) Experimental approaches to evaluate the thermodynamics of protein-drug interactions. Curr Drug Targets 9: 1071-1076.
3. Seeliger D, de Groot BL, (2010) Conformational transitions upon ligand binding: holo-structure prediction from apo conformations. PLoS Comput Biol 6: e1000634.
4. Zhang R, Monsma F, (2009) The importance of drug-target residence time. Curr Opin Drug Discov Devel 12: 488-496.
5. Copeland RA, Pompliano DL, Meek TD, (2006) Drug-target residence time and its implications for lead optimization. Nat Rev Drug Discov 5: 730-739.
6. O'Sullivan DG, Wallis AK, (1963) New benzimidazole derivatives with powerful protective action on tissue-culture cells infected with types 1, 2, and 3 polio virus. Nature 198: 1270.
7. Akihama S, Okude M, Sato K, Iwabuchi S, (1968) Inhibitory effect of 1,2-bis(2-benzimidazolyl)-1,2-ethanediol derivatives on poliovirus. Nature 217: 562-563.
8. Shipkowitz NL, Bower RR, Schleicher JB, Aquino F, Appell RN, et al. (1972) Antiviral activity of a bis-benzimidazole against experimental rhinoviru infections in chimpanzees. Appl Microbiol 23: 117-122.
9. Tavman A, Birteksöz S, Otük G, (2005) Antimicrobial activity of 1,2-bis-[2-(5-R)-1H benzimidazolyl]- 1,2-ethanediols, 1,4-bis-[2-(5-R)-1H-benzimidazolyl]- 1,2,3,4 butanetetraols and their FeIII, CuII, and AgI complexes. Folia Microbiol (Praha) 50: 467-472.
10. Isele K, Broughton V, Matthews CJ, Williams AF, Bernardinelli G, et al. (2002) 1,2-Bis(2- benzimidazolyl)-1,2-ethanediol, a chiral, tridentate, facially coordinating ligand. J Chem Soc Dalton Trans 3899-3905.
11. Peters T Jr (1996) All about albumin: biochemistry, genetics and medical application. Academic Press, Inc.: New York.
12. Sudlow G, Birkett DJ, Wade DN, (1975) The Characterization of Two Specific Drug Binding Sites on Human Serum Albumin. Mol Pharmacol 11: 824-832.
13. Sjöholm I, Ekman B, Kober A, Ljungstedt-Pahlman I, Seiving B, et al. (1979) Binding of drugs to human serum albumins, Mol Pharmacol. 16: 767-777.
14. Ryan CW, Vogelzang NJ, Vokes EE, Kindler HL, Undevia SD, et al. (2004) Dose-ranging study of the safety and pharmacokinetics of atrasentan in patients with refractory malignancies. Clin Cancer Res 10: 4406-4411.
15. Schmidt S, Röck K, Sahre M, Burkhardt O, Brunner M, et al. (2008) Effect of protein binding on the pharmacological activity of highly bound antibiotics. Antimicrob Agents Chemother 52: 3994-4000.
16. Ahmad B, Lapidus LJ, (2012) Curcumin prevents aggregation in α-synuclein by increasing reconfiguration rate. J Biol Chem 287: 9193-9199.
17. Hung HC, Liu CL, Hsu JT, Horng JT, Fang MY, et al. (2012) Development of an anti-influenza drug screening assay targeting nucleoproteins with tryptophan fluorescence quenching. Anal Chem 84: 6391-6399.
18. Ahmad B, Parveen S, Khan RH, (2006) Effect of albumin conformation on the binding of ciprofloxacin to human serum albumin: a novel approach directly assigning binding site. Biomacromolecules 7: 1350-1356.
19. Han XL, Tian FF, Ge YS, Jiang FL, Lai L, et al. (2012) Spectroscopic, structural and thermodynamic properties of chlorpyrifos bound to serum albumin: A comparative study between BSA and HSA. J Photochem Photobiol B 109: 1-11.
20. Peters T Jr, (1985) Serum albumin. Adv Protein Chem 37: 161-245.
21. Louis-Jeune C, Andrade-Navarro MA, Perez-Iratxeta C, (2012) Prediction of protein secondary structure from circular dichroism using theoretically derived spectra. Proteins Structure, Function, and Bioinformatics 80: 374-381.
22. Tanford C, (1968) Protein denaturation. Adv Protein Chem 23: 122-282.
23. Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, et al. (2004) Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J med chem 47: 1739-1749.
24. Halgren TA, Murphy RB, Friesner RA, Beard HS, Frye LL, et al. (2004) Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J med chem 47: 1750-1759.
25. Ghuman J, Zunszain PA, Petitpas I, Bhattacharya AA, Otagiri M, et al. (2005) Structural basis of the drug-binding specificity of human serum albumin. J Mol Biol 353: 38-52.
26. Majorek KA, Porebski PJ, Dayal A, Zimmerman MD, Jablonska K, et al. (2012) Structural and immunologic characterization of bovine, horse, and rabbit serum albumins. Mol Immunol 52: 174-182.
27. Friesner RA, Murphy RB, Repasky MP, Frye LL, Greenwood JR, et al. (2006) Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J Med Chem 49: 6177-6196.
28. Kume S, Lee YH, Miyamoto Y, Fukada H, Goto Y, et al. (2012) Systematic interaction analysis of human lipocalin-type prostaglandin D synthase with small lipophilic ligands. Biochem J 446: 279-89.
29. Eftink MR, Ghiron CA, (1981) Fluorescence quenching studies with proteins. Anal Biochem 114: 199-227.
30. Lakowicz JR (2004) Principles of fluorescence spectroscopy. 2nd Edition, Springer, New York.
31. Ware WR, (1962) Oxygen quenching of fluorescence in solution: An experimental study of the diffusion process. J Phys Chem 66: 455-458.
32. Coan KE, Shoichet BK, (2008) Stoichiometry and physical chemistry of promiscuous aggregate-based inhibitors. J Am Chem Soc 130: 9606-9612.
33. Owen SC, Doak AK, Wassam P, Shoichet MS, Shoichet BK, (2012) Colloidal aggregation affects the efficacy of anticancer drugs in cell culture. ACS Chem Biol 7: 1429-1435.
34. Kang J, Liu Y, Xie MX, Li S, Jiang M, et al. (2004) Interactions of human serum albumin with chlorogenic acid and ferulic acid. Biochim Biophys Acta. 1674: 205-214.
35. Agudelo D, Bourassa P, Bruneau J, Bérubé G, Asselin E, et al. (2012) Probing the Binding Sites of Antibiotic Drugs Doxorubicin and N-(trifluoroacetyl)Doxorubicin with Human and Bovine Serum Albumins. PLoS One 7: e43814.
36. Wallevik K, (1973) Reversible denaturation of human serum albumin by pH, temperature and guanidine hydrochloride. J Biol Chem 245: 2650-2655.
37. Tummino PJ, Copeland RA, (2008) Residence time of receptor-ligand complexes and its effect on biological function. Biochemistry 47: 5481-5492.
38. Copeland RA, (2010) The dynamics of drug-target interactions: drug-target residence time and its impact of efficacy and safety. Expert Opin Drug Discov 5: 305-310.
39. Creighton TE (1993) Proteins:structure and molecular properties, W.H. Freeman and Company, New York.
40. Tayyab S, Ahmad B, Kumar Y, Khan MM, (2002) Salt-induced refolding in different domains of partially folded bovine serum albumin. Int J Biol Macromol 30: 17-22.
41. Ahmad B, Khan MK, Haq SK, Khan RH, (2004) Intermediate formation at lower urea concentration in 'B' isomer of human serum albumin: a case study using domain specific ligands. Biochem Biophys Res Commun 314: 166-173.
42. Bagatolli LA, Kivatinitz SC, Fidelio GD, (1996) Interaction of small ligands with human serum albumin IIIA subdomain. How to determine the affinity constant using an easy steady state fluorescent method. J Pharm Sci 85: 1131-1132.
43. Patel AB, Srivastava S, Phadke RS, (1999) Interaction of 7-hydroxy-8-(phenylazo)1,3 naphthalenedisulfonate with bovine plasma albumin. Spectroscopic studies. J Biol Chem 274: 21755-62.
44. Dubeau S, Bourassa P, Thomas TJ, Tajmir-Riahi HA, (2010) Biogenic and synthetic plyamines bind bovine serum albumin. Biomacromolecules 11: 1507-1515.
45. Charbonneau DM, Tajmir-Riahi HA, (2010) Study on the interaction of cationic lipids with bovine serum albumin. J Phys Chem B 114: 1148-1155.
46. Bourassa P, Kanakis DC, Tarantilis PA, Polissiou MG, Tajmir-Riahi HA, (2010) Resveratrol, genistein and curcumin bind human serum albumin. J Phys Chem B 114: 3348-3354.
47. Narazaki R, Maruyama T, Otagiri M, (1997) Probing the cysteine 34 residue in human serum albumin using fluorescence techniques. Biochim Biophys Acta 1338: 275-281.
48. Ahmad E, Rabbani G, Zaidi N, Ahmad B, Khan RH, (2012) Pollutant-induced modulation in conformation and β-lactamase activity of human serum albumin. PLoS One 7: e38372.
49. Waldron TT, Murphy KP, (2003) Stabilization of proteins by ligand binding: application to drug screening and determination of unfolding energetics. Biochemistry 42: 5058-5064.
50. Strunk JJ, Gregor I, Becker Y, Li Z, Gavutis M, et al. (2008) Ligand binding induces a conformational change in ifnar1 that is propagated to its membrane-proximal domain. J Mol Biol 377: 725-739.